Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 19, 2020
Daily News
May 19, 2020
- JCR Aims to File Sakigake-Designated Hunter Syndrome Drug in September
May 19, 2020
- Mitsubishi Tanabe, Fuso to Copromote HIF-PH Inhibitor
May 19, 2020
- Nichi-Iko Launches Another Recall, Now Pulling 8 More APIs/9 Products
May 19, 2020
- Check Latest Info and Make Careful Decision on Veklury Use: PMDA Review Report
May 19, 2020
- MHLW Panel to Discuss HIF-PH Inhibitors from GSK, Mitsubishi Tanabe on May 29
May 19, 2020
- Medicago’s COVID-19 Vaccine Shows Positive Animal Data, Clinical Trial Expected to Wrap Up by November 2021
May 19, 2020
- Enhertu Gets FDA’s Breakthrough Therapy Status for NSCLC
May 19, 2020
- MHLW Panel to Discuss Orphan Status for 5 Cell and Gene Products
May 19, 2020
- Health Ministers of Japan, China, South Korea Commit to Support WHO on COVID-19, Timely Share Info
May 19, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…